All In Biotech

Drug Trial Radar · NCT05828472

A Study of Multiple Ascending Doses MY008211A in Healthy Adults

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Doses Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of MY008211A Tablets in Healthy Adult Volunteers

Last checked: Nov 20, 2026Latest source record: Sep 8, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

40

Actual

Start

Jan 10, 2023

Primary completion

Jun 30, 2023

Study completion Jun 30, 2023

Sponsor

Sponsor type
Industry
First posted
Apr 25, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a single-center, randomized, double-blind, placebo-controlled, dose-escalation, and multiple-dose study to evaluate safety, tolerability, PK and PD of MY008211A Tablets in healthy subjects.

Conditions

  • Paroxysmal Nocturnal Hemoglobinuria

Interventions

  • MY008211A tabletsDrug

    MY008211A tablets, low/moderate/high dose orally, for 7 days

  • MY008211A tablets matched placeboDrug

    MY008211A tablets matched placebo, low/moderate/high dose orally, for 7 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The incidence and severity of adverse events to assess safety and tolerabilityTime frame: up to 31 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Third Hospital of Changsha

    Changsha, Hunan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.